Skip to main content
. 2019 Jan 25;24(5):657–663. doi: 10.1634/theoncologist.2018-0271

Figure 5.

image

Photographs of a 43‐year‐old female patient with stage IV ERC1‐BRAF fusion melanoma, taken before (A, C) and after (B, D) 2 months of oral sorafenib 400 mg b.i.d. Subcutaneous metastases of the anterior part of the trunk (A, B) and subcutaneous metastases of the back (C, D), responding to sorafenib, after progressing under immunotherapy.